Pharmac has included the weight-loss drug Wegovy in its future funding list, with eligibility based on BMI and comorbidities, amid concerns over cost and effectiveness.
Stacked weekly counts; colour by editorial lean. Stuff and The Spinoff lean centre-left, NZ Herald centre-right, others centre.
How press outlets have named this topic, week by week.
Most recent 3 articles linking to this topic.
Up to 12 framings spread across outlets. Each framing is the LLM's one-line characterisation of the article's editorial angle — not a quote.
drug affordability critical for health outcomes
Funding of weight-loss drug Wegovy expected to come swiftlyobesity costs exceed medical spending in NZ
I prefer to remain overweight rather than overmedicatedSocial-media signal on the same topic, drawn from the social lens. Engagement is likes + 2×shares + 3×replies, the same weighting used across the digest cards. View on /social →
Spotted something wrong on this page? Report a correction.
